Zacks: Analysts Anticipate Teladoc Inc (TDOC) to Announce -$0.43 EPS

Equities research analysts expect Teladoc Inc (NYSE:TDOC) to announce earnings of ($0.43) per share for the current quarter, according to Zacks. Nine analysts have provided estimates for Teladoc’s earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.38). Teladoc reported earnings of ($0.30) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 43.3%. The business is expected to issue its next quarterly earnings results on Monday, May 14th.

On average, analysts expect that Teladoc will report full-year earnings of ($1.37) per share for the current year, with EPS estimates ranging from ($1.41) to ($1.28). For the next year, analysts expect that the company will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.18) to ($0.41). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Teladoc.

How to Become a New Pot Stock Millionaire

Teladoc (NYSE:TDOC) last announced its quarterly earnings results on Tuesday, February 27th. The health services provider reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.10). Teladoc had a negative net margin of 45.77% and a negative return on equity of 20.95%. The firm had revenue of $77.14 million for the quarter, compared to analyst estimates of $76.14 million.



Several brokerages have recently issued reports on TDOC. KeyCorp reissued an “overweight” rating and set a $50.00 price target (up previously from $41.00) on shares of Teladoc in a report on Thursday, March 15th. Deutsche Bank downgraded shares of Teladoc from a “buy” rating to a “hold” rating and set a $45.00 price target for the company. in a report on Thursday, March 15th. Wells Fargo set a $46.00 price target on shares of Teladoc and gave the company a “buy” rating in a report on Friday. Canaccord Genuity boosted their price target on shares of Teladoc from $43.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Finally, Chardan Capital reissued a “buy” rating and set a $47.00 price target (down previously from $48.00) on shares of Teladoc in a report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Teladoc presently has an average rating of “Buy” and a consensus price target of $41.67.

In other Teladoc news, CFO Mark Hirschhorn sold 100,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.60, for a total value of $3,960,000.00. Following the completion of the sale, the chief financial officer now directly owns 98,960 shares of the company’s stock, valued at approximately $3,918,816. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jason N. Gorevic sold 40,000 shares of the company’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $43.27, for a total transaction of $1,730,800.00. The disclosure for this sale can be found here. Insiders sold 364,494 shares of company stock valued at $14,665,947 in the last ninety days. Corporate insiders own 4.47% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in Teladoc by 2.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 285,788 shares of the health services provider’s stock valued at $9,474,000 after acquiring an additional 6,396 shares during the last quarter. Strs Ohio lifted its holdings in Teladoc by 33.3% in the 4th quarter. Strs Ohio now owns 304,226 shares of the health services provider’s stock valued at $10,602,000 after acquiring an additional 76,057 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in Teladoc by 33.2% in the 3rd quarter. New York State Common Retirement Fund now owns 90,513 shares of the health services provider’s stock valued at $3,001,000 after acquiring an additional 22,554 shares during the last quarter. ARK Investment Management LLC lifted its holdings in Teladoc by 211.7% in the 4th quarter. ARK Investment Management LLC now owns 31,321 shares of the health services provider’s stock valued at $1,092,000 after acquiring an additional 21,274 shares during the last quarter. Finally, Gamco Investors INC. ET AL acquired a new stake in Teladoc in the 4th quarter valued at about $941,000.

Shares of TDOC traded down $0.45 during midday trading on Monday, hitting $38.70. 743,888 shares of the stock traded hands, compared to its average volume of 1,097,676. Teladoc has a 1-year low of $22.73 and a 1-year high of $44.65. The company has a market cap of $2,416.59, a price-to-earnings ratio of -23.45 and a beta of 0.36. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.87 and a current ratio of 3.87.

ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://stocknewstimes.com/2018/04/16/zacks-analysts-anticipate-teladoc-inc-tdoc-to-announce-0-43-eps.html.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Get a free copy of the Zacks research report on Teladoc (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply